INHIBITORS OF TRPC6 - Boehringer Ingelheim International GmbH
Summary
The European Patent Office published patent application EP3752503A1 for TRPC6 inhibitors assigned to Boehringer Ingelheim International GmbH. The patent covers therapeutic compounds for cardiovascular, respiratory, and neurological applications. The application designates all EPC contracting states including Germany, France, United Kingdom, Italy, and Spain.
What changed
The EPO published a patent application (EP3752503A1) for inhibitors of TRPC6 (Transient Receptor Potential Cation Channel Subfamily C Member 6) filed by Boehringer Ingelheim International GmbH. The application includes IPC classifications spanning heterocyclic compounds (C07D series) and pharmaceutical compositions (A61K/A61P series) targeting cardiovascular (A61P9/00), respiratory (A61P11/00), and neurological (A61P25/00) conditions.
Pharmaceutical companies engaged in drug development should review this patent publication to assess potential freedom-to-operate concerns in the European market. Competitors developing TRPC6 inhibitors or related therapeutic compounds may need to evaluate the scope of the claims or consider potential design-around strategies. The designated contracting states cover the major European pharmaceutical markets.
What to do next
- Monitor for updates on related patent family applications
- Review patent claims for potential freedom-to-operate implications
Archived snapshot
Apr 16, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
INHIBITORS OF TRPC6
Publication EP3752503A1 Kind: A1 Apr 08, 2026
Applicants
Boehringer Ingelheim International GmbH
Inventors
BERRY, Angela Kay, BOUYSSOU, Thierry, GOTTSCHLING, Dirk, HEINE, Niklas, NETHERTON, Matthew Russell
IPC Classifications
C07D 413/14 20060101AFI20190823BHEP C07D 401/04 20060101ALI20190823BHEP C07D 403/04 20060101ALI20190823BHEP C07D 407/14 20060101ALI20190823BHEP C07D 417/14 20060101ALI20190823BHEP A61K 31/44 20060101ALI20190823BHEP A61K 31/501 20060101ALI20190823BHEP A61K 31/496 20060101ALI20190823BHEP A61P 9/00 20060101ALI20190823BHEP A61P 11/00 20060101ALI20190823BHEP A61P 25/00 20060101ALI20190823BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.